Allopurinol Prescription Patterns among Patients Attending Primary Health Care Centers in Qatar: A Retrospective Cross-Sectional Study
Allopurinol
Medical record
DOI:
10.29011/2688-7460.100241
Publication Date:
2023-12-26T05:33:15Z
AUTHORS (5)
ABSTRACT
Introduction: Hyperuricemia is a medical condition associated with an increased incidence of comorbidities. Guidelines for the treatment asymptomatic hyperuricemia remain controversial. Several studies have reported that allopurinol overused worldwide. In Qatar, no national guidelines management or previous evaluated over prescription. The study aimed to determine frequency overtreatment and investigate factors. Methods: retrospective cross-sectional was conducted in Qatar on adult patients who were prescribed first time at Primary Health Care Corporation between 01 July 2021 June 30, 2022. Data extracted from patients’ electronic records. Appropriate use defined as presence gout, kidney stones, disease, evidence tophi, extremely high serum uric acid levels (>773.24 mmol/L men >594.8 women), ongoing chemotherapy malignancy patients. Results: Our included 1949 received their mean age 45.66 years (standard deviation=10.57), male predominance (75%). Only 17.39% natives while remaining expatriates. top three comorbidities hypertension, dyslipidemia, diabetes (44.38%, 42.74%, 30.17%, respectively). Seventeen had diagnosis prescriptions. Most diagnoses related gout (45.29% 21.48%, Among 1932 patients, only 25.26% appropriate most commonly dose “100 mg daily” (89.38%). A statistically significant difference discovered inappropriate prescriptions terms sex (p<0.001). Diabetes, chronic cerebrovascular disease risk prescriptions, p-values 0.012, 0.025, <0.001, 0.044, respectively. Normal abnormal significantly whereas all “extremely high” valid Discussion: revealed primary care facilities not indicated. implementation clinical highly recommended.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....